HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER		Author Keyword(s) Vol Page [Advanced]

This Article Full Text Full Text (PDF) All Versions of this Article: jcp.2005.033407v1 60/5/483    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this link to a friend Similar articles in this journal Similar articles in PubMed Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Woenckhaus, M. Articles by Wild, P. J Search for Related Content PubMed PubMed Citation Articles by Woenckhaus, M. Articles by Wild, P. J Pubmed/NCBI databases Medline Plus Health Information Lung Cancer

Nuclear and cytoplasmic Maspin expression in primary non-small cell lung cancer

¹ Institute of Pathology, University of Regensburg, Regensburg, Germany
² Institute of Pathology, University of Basel, Basel, Switzerland
³ Department of Pathology, University of Vermont College of Medicine, Burlington, Vermont, USA
⁴ Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
⁵ Pulmonary Division, Department of Internal Medicine, University of Basel, Basel, Switzerland

Correspondence to:
Dr M Woenckhaus
Institute of Pathology, University of Regensburg, Franz-Josef-Strauss-Allee 11, D-93053 Regensburg, Germany; matthias.woenckhaus{at}klinik.uni-r.de Aim: To investigate whether nuclear and cytoplasmic Maspin expression is associated with distinct clinicopathological parameters and TP53 expression in a representative series of primary non-small cell lung cancer (NSCLC).

Methods: Tissue microarrays (n = 487) were used to immunohistochemically analyse expression of Maspin and TP53. Cytoplasmic and nuclear expression of Maspin was scored on the basis of the percentage of positive tumour cells. Univariate analysis of clinicopathological variables potentially affecting tumour-specific survival was performed.

Results: Immunohistochemical Maspin expression (nuclear and cytoplasmic) was informative in 72.3% (352/487) of cases. Cytoplasmic and nuclear Maspin immunoreactivity in 10% of tumour cells was detected in 37.8% (133/352) and 65.3% (230/352) of informative cases, respectively. Nuclear and cytoplasmic Maspin staining was observed more frequently in primary squamous cell carcinomas than in other lung cancer types. Only nuclear Maspin immunoreactivity was significantly associated with positive TP53 staining. Cytoplasmic or nuclear Maspin expression was not associated with tumour-specific survival.

Conclusion: Maspin expression was found both in the nucleus and the cytoplasm of NSCLC, more frequently in squamous cell carcinomas. However, no association with tumour-specific survival could be demonstrated.